JDD HighlightsJDD in the MediaThe Latest

JDD in the News: Chlorophyll for Clear Skin, Depression & Isotretinoin

By May 26, 2021July 15th, 2021No Comments

In The News

In the News

JDD Impact Factor and Influence

The Journal of Drugs in Dermatology is featured in two recent articles about the latest TikTok trend — chlorophyll.

More on Chlorophyll

The Journal of Drugs in Dermatology in the News 

Allison Sit

The Journal of Drugs in Dermatology is featured in two recent articles about the latest TikTok trend — chlorophyll. Users claim products that contain chlorophyllin – a water-soluble version of chlorophyll — clear the skin, reduce bloating and help with weight loss. Both articles, “Liquid Chlorophyll: What to Know Before Buying,” by NBC News, and “Should You Hop on the Chlorophyll Wellness Trend?” by L’Officiel address the nutritional benefits of chlorophyll and ways to consume more of it.

The articles both cite a 2015 JDD study, “Pilot Study of Topical Copper Chlorophyllin Complex in Subjects With Facial Acne and Large Pores,” by Thomas J. Stephens, PhD, John P. McCook, and Dr. James H. Herndon, Jr. The study found a topical formulation containing a liposomal dispersion of sodium copper chlorophyllin complex to be clinically effective and well tolerated for the treatment of mild to moderate acne and large, visible pores when used for 3 weeks.

Dermatology Times highlighted a JDD study in its article, “Depression, Distress Different Between Patients Treated with Isotretinoin and Oral Antibiotics.” The article cites a February 2021 study, “Differences in Depression and Distress Between Acne Patients on Isotretinoin vs Oral Antibiotics” by Dr. April Armstrong and researchers. The study analyzed acne patients’ responses to Patient Health Questionnaire 2 and the Kessler 6-Item Psychological Distress Scale. Researchers found acne patients on isotretinoin experienced fewer depressive symptoms and psychological distress compared to patients on oral antibiotics.

The Dermatology Digest also wrote about the JDD study on depression and isotretinoin in its April print edition. The publication also published briefs on two other 2021 JDD articles, “Laboratory Testing in Telogen Effluvium,” and “Intralesional 5-Fluorouracil for Treatment of Non-Melanoma Skin Cancer: A Systematic Review.”

You May Also Like

From the Vault: Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris

| Acne, Featured Articles, Latest News, The Latest | No Comments
Clascoterone Keeps Gaining Ground in Acne Two identical Phase 3 trials (plus a long‑term extension) randomized patients ≥12 years with moderate‑to‑severe acne to twice‑daily clascoterone 1% cream or vehicle for…
Journal of Drugs in Dermatology JDD Article About Microneedling Combined With Drugs and Stem Cells for Treating Androgenetic Alopecia

Microneedling Combined With Drugs and Stem Cells for Treating Androgenetic Alopecia

| Alopecia, Featured Articles, Latest News, The Latest | No Comments
Small Channels, Smarter Delivery -  A Practical Boost For Topical And Regenerative Approaches Microneedling is proving to be a low‑risk, clinic-friendly way to enhance topical therapies (most consistently 5% minoxidil, now…
Journal of Drugs in Dermatology JDD Article About The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients With Atopic Dermatitis: A Retrospective Chart Review

The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients With Atopic Dermatitis: A Retrospective Chart Review

| Atopic Dermatitis, Featured Articles, Latest News, The Latest | No Comments
Dupilumab in Diverse Skin — Are Adverse Events Really the Same? Atopic dermatitis isn’t one-size-fits-all: chronic type 2 inflammation, barrier dysfunction, and S. aureus colonization are core features, but presentation…

Leave a Reply